On August 30, 2024, Alexion Pharmaceuticals, Inc. and Alexion Pharma International Operations Ltd. (collectively, “Alexion”) and Samsung Bioepis Co. Ltd. (“Samsung Bioepis”) settled their ...

Superbugs that are increasingly resistant to infections could kill up to 40 million people between now and 2050, according to new research published in the journal The Lancet. During that time ...

It is expected to cause more than 39 million more fatalities by 2050 — three per minute. That’s according to a large study led by the Global Research on Antimicrobial Resistance (GRAM ...

Cumulatively, from 2025 to 2050, the world could see more than 39 million deaths that are directly attributable to antimicrobial resistance or AMR, according to the study, which was published ...

It is expected to cause more than 39 million more fatalities by 2050 — three per minute. That’s according to a large study led by the Global Research on Antimicrobial Resistance (GRAM ...

Alexion has said it can ramp up production if the drug works in trials but what it has not mentioned is its cost: Ultomiris is hugely expensive when used in rare diseases, costing several thousand ...

These trends are expected to continue, with AMR deaths among children under 5 projected to halve by 2050 and deaths among people 70 years and over expected to more than double. The study, conducted by ...

The 2070 fund starts with about 96% equity stakes, which begins to decline 25 years before retirement (currently the 2050 fund). At retirement, the series notably counts roughly 47% of assets in ...

A straightforward glide path delivers vintages in five-year increments from 2065 through 2010. Starting with 97% equity exposure, that weighting drops 20 percentage points over the first 25 years.

COP27 is in full swing and world leaders are contending with the fact that we will likely not meet the Paris Agreement’s 1.5°C target. The reality is that we will need to focus on limiting a ...

The forecast and scenarios of AMR burden to 2050 are also subject to the limitations in the historical estimates, including availability and quality of historical data. The forecast models also do not ...